Drug Marketing and Advertising Are You Prepared for the Challenges of Social Media?

$327.00
Held Nov. 19, 2009

Since the FDA cracked down on social media marketing and online advertising, drugmakers have been walking on eggshells. A key FDA meeting is scheduled for Nov. 12–13. Read on ...

Internet marketing and social media offer powerful new tools to communicate the benefits of your drugs and biologics. But with the FDA a threatening question mark, it’s hard to know how to move forward.

What are the best practices firms can employ while the FDA determines its approach to regulating social media and internet advertising?

Consult the experts.

Dr. Mark DeWyngaert is a leading consultant in drug sales and marketing, he helps drug and biologic makers thread through the FDA maze. Alan Bennett is managing partner in the Washington, D.C. office of Ropes & Gray and has represented clients at the FDA and in Congress on many of the critical issues that affect the pharmaceutical industry. We’ve invited them to spend 90 minutes with you, explaining what the FDA is doing, where it’s heading, and how you can meet your marketing goals — without crossing regulatory boundaries.

In 90 fast-paced minutes, without ever leaving the convenience of your office, you’ll have the opportunity to pick our experts brains — at a cost that’s a fraction of what you’d pay for an on-site consulting visit. They’ll fill you in on key points from the November public meeting and help you prepare for whatever new FDA strategies emerge. Here’s just a taste of this webinar’s agenda:
  • The 5 issues DDMAC is citing in enforcement letters
  • How current regulations and guidance apply to your particular situation
  • The 3 main types of social media: user-generated content, bookmarking and sharing, and social networking
  • What YouTube, Wikipedia, Facebook, Linked-in and Twitter have in common, and how consumers are using them
  • The 6 types of adult online consumers
  • Social media advertising trends
  • How brand reputation is affected by growing product awareness, patient interaction and portability
  • Social media tools — which are high risk, which are low risk
  • Developing an innovative social media monitoring program
  • Using social media monitoring and text mining to create models and identify consumer trends
  • And plenty more!

Because this seminar is web-based and totally interactive, you’ll have plenty of opportunity to email all your questions and receive answers before the session ends.

Advertising and marketing cut across many company departments and functions. Dozens in your company may wish to attend. That’s no problem. As many personnel may log on as you like — for one low registration fee. There are no restrictions except that all registrants must be at the same company location.

The FDA has made no bones about plans to step up enforcement, and DDMAC is at the forefront of agency plans. Now is the time to prepare. Make plans now to log on for this one-time-only session.

  • Compliance officers
  • Sales and marketing professionals
  • Medical affairs personnel
  • General/corporate counsel
  • Regulatory/legislative affairs professionals
  • Communications/public relations professionals

Phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600

Dr. Mark DeWyngaert is a managing director in the Life Sciences Advisory Practice at Huron Consulting. Trained as a molecular biologist, he specializes in assisting pharmaceutical manufacturers, biotechnology and medical device companies with identifying and mitigating regulatory risks and valuing intellectual property. As a consultant, he leads teams in the assessment of sales and marketing, medical affairs and clinical development activities, and he assists companies in the redesign of business practices to comply with regulations and standards.

Alan Bennett is managing partner in the Washington, D.C. office of Ropes & Gray and formerly served as co-chair of the firm’s Life Sciences Group. He focuses on legal issues surrounding the development and marketing of medical products and has served as outside counsel to many pharmaceutical and medical device firms. Alan’s practice at Ropes & Gray has involved counseling clients, and representing them at the FDA and in Congress, on many of the critical issues that affect the pharmaceutical industry. He is a recognized expert on issues that arise under the Hatch-Waxman Act, as well as on issues involving pharmaceutical marketing, promotion and education.

Order now!